Orum Therapeutics
Youngji HONG has a diverse work experience in various roles and industries. From 2012 to 2015, they worked as a Research Project Manager at Sanofi. In 2015, they joined CHA Medical Group as a Project Manager until 2016. Youngji then moved on to Orum Therapeutics, where they initially served as the KR Operations Manager from 2016 to 2019 before being promoted to the position of US Operations Manager in September 2019, a role they currently hold.
Youngji Hong earned a Bachelor's degree in Business Administration and Management, General from Ewha Womans University, which they attended from 2005 to 2012. In 2008, they also participated in the ESPEME program as an exchange student at EDHEC Business School. Youngji'sfield of study for both institutions was Business Administration and Management, General.
This person is not in any offices
Orum Therapeutics
Orum Therapeutics is a private biotech company developing a new class of therapeutic antibodies targeting cytosolic proteins for unmet medical needs in cancer and rare diseases. Orum leverages its unique cell-penetrating antibody platform, called Oromab™ to inhibit drug targets, previously undruggable by small molecules or current antibodytherapeutics. In contrast to other approaches, Orum’s antibody platform can intracellularly deliver an active antibody therapeutic or payload, is easily adaptable to target different cell types and intracellular proteins, and does not require chemical modification.